A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer.

Jung-Yun Lee Kyung Jin Eoh Eun Ji Nam Sunghoon Kim Sang-Wun Kim Young-Tae Kim Jung-Yun Lee

Published in: Yonsei medical journal (2020)

Bevacizumab-containing NAC might be safe and provide longer PFS than chemotherapy alone in patients with advanced ovarian cancer. However, further study is necessary to investigate the impact of bevacizumab-containing NAC on OS.

Keyphrases

neoadjuvant chemotherapy
locally advanced
metastatic colorectal cancer
transcription factor
lymph node
sentinel lymph node
rectal cancer
minimally invasive
coronary artery bypass
genome wide analysis
coronary artery disease
early stage
surgical site infection